Healthcare provider profile · identity verified

Sean Li, MD

Allopathic & Osteopathic Physicians|Plastic Surgery · PHILADELPHIA, PA · NPI 1699124438

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Sean Li, MD received $7,654.93 in general payments during 2025 across 40 reported records.

RTI SURGICAL, INC accounted for 52.1% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 20 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$7,654.93

40 reported records · 13 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
RTI SURGICAL, INC Unresolved — no canonical attribution shown $3,989.9152.1%62025
Stryker Corporation Unresolved — no canonical attribution shown $1,481.8219.4%102025
Davol Inc. Unresolved — no canonical attribution shown $849.8511.1%32025
Mentor Worldwide LLC Unresolved — no canonical attribution shown $755.789.9%92025
Medtronic, Inc. Medtronic, Inc.
exact · evidence 2025-07-22
$162.222.1%12025
Solventum Corporation Unresolved — no canonical attribution shown $154.552.0%22025
Integra LifeSciences Corporation Unresolved — no canonical attribution shown $76.531.0%22025
Biocomposites Inc Unresolved — no canonical attribution shown $61.000.8%12025
ABBVIE INC. Unresolved — no canonical attribution shown $32.340.4%12025
Musculoskeletal Transplant Foundation Inc. Unresolved — no canonical attribution shown $27.140.3%22025
ConvaTec Inc. Unresolved — no canonical attribution shown $26.480.3%12025
VERTEX PHARMACEUTICALS INCORPORATED Unresolved — no canonical attribution shown $23.620.3%12025
MOTIVA USA, LLC Unresolved — no canonical attribution shown $13.690.2%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Honoraria$4,412.504
Food and Beverage$2,330.9233
Travel and Lodging$911.513

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
CORTIVA ALLOGRAFT DERMIS
Normalized: cortiva allograft dermis
Device RTI SURGICAL, INC $3,989.91 6 2025
Source payment records
1788
Normalized: 1788
Medical Supply Stryker Corporation $1,261.04 7 2025
Source payment records
MENTOR MemoryGel Resterilizable Gel Sizer
Normalized: mentor memorygel resterilizable gel sizer
Device Mentor Worldwide LLC $755.78 9 2025
Source payment records
ARTOURA Breast Tissue Expander
Normalized: artoura breast tissue expander
Device Mentor Worldwide LLC $398.58 5 2025
Source payment records
SPY-PHI SYSTEM
Normalized: spy phi system
Device Stryker Corporation $220.78 3 2025
Source payment records
MOLLI
Normalized: molli
Device Stryker Corporation $199.89 2 2025
Source payment records
ENDURANT IIS
Normalized: endurant iis
Device Medtronic, Inc. $162.22 1 2025
Source payment records
PREVENA
Normalized: prevena
Device Solventum Corporation $154.55 2 2025
Source payment records
MENTOR CPX 2 Breast Tissue Expander
Normalized: mentor cpx 2 breast tissue expander
Device Mentor Worldwide LLC $114.50 1 2025
Source payment records
Integra
Normalized: integra
Device Integra LifeSciences Corporation $76.53 2 2025
Source payment records
Integra Dermal Regeneration Template
Normalized: integra dermal regeneration template
Device Integra LifeSciences Corporation $76.53 2 2025
Source payment records
OMNIGRAFT
Normalized: omnigraft
Device Integra LifeSciences Corporation $76.53 2 2025
Source payment records
SURGIMEND
Normalized: surgimend
Device Integra LifeSciences Corporation $76.53 2 2025
Source payment records
Stimulan
Normalized: stimulan
Device Biocomposites Inc $61.00 1 2025
Source payment records
ALLODERM
Normalized: alloderm
Device ABBVIE INC. $32.34 1 2025
Source payment records
AQUACEL AG+ EXTRA
Normalized: aquacel ag extra
Device ConvaTec Inc. $26.48 1 2025
Source payment records
JOURNAVX
Normalized: journavx
Drug VERTEX PHARMACEUTICALS INCORPORATED $23.62 1 2025
Source payment records
Phasix Mesh
Normalized: phasix mesh
Device Davol Inc. $20.43 1 2025
Source payment records
ARISTA
Normalized: arista
Device Davol Inc. $16.92 1 2025
Source payment records
Motiva Implant Matrix
Normalized: motiva implant matrix
Device MOTIVA USA, LLC $13.69 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Tramadol HclTramadol Hcl1813
Ondansetron OdtOndansetron1311
CefadroxilCefadroxil12suppressed
GabapentinGabapentin12suppressed
IbuprofenIbuprofen12suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $7,654.93 · 40 records RTI SURGICAL, INC 1788, ALLODERM, AQUACEL AG+ EXTRA, ARISTA, ARTOURA Breast Tissue Expander, CORTIVA ALLOGRAFT DERMIS, ENDURANT IIS, Integra, Integra Dermal Regeneration Template, JOURNAVX, MENTOR CPX 2 Breast Tissue Expander, MENTOR MemoryGel Resterilizable Gel Sizer, MOLLI, Motiva Implant Matrix, OMNIGRAFT, PREVENA, Phasix Mesh, SPY-PHI SYSTEM, SURGIMEND, Stimulan
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error